Lung fibroblasts are considered as the key effector cells in Idiopathic Pulmonary Fibrosis (IPF), an interstitial lung disease that commonly seen in elderly with unclear etiology. Characterized by excessive fibroproliferation and extracellular matrix accumulation, IPF is associated with progressive decline in lung function, poor diagnosis, and limited treatment option. Studies have suggested that transforming growth factor (TGF)-β induced alveolar epithelial cells (AEC) can undergo epithelial-mesenchymal transition (EMT) and serve as a source of fibroblast or myofibroblast in fibrosis. Aging is also a main contributor to IPF where senescence fibroblasts show abnormal metabolism and senescence-associated secretory phenotypes.
Why Choose Diseased Human Lung Fibroblasts, Idiopathic Pulmonary Fibrosis from AcceGen?
AcceGen Human lung fibroblasts IPF are derived from patients with idiopathic pulmonary fibrosis. IPF lung fibroblasts are isolated by enzymatic digestion and cryopreserved at passage 2. Each vial contains > 5×10^5 cells in 1 ml volume. Human primary IPF lung fibroblasts are characterized with spindle-shaped morphology and tested negative for von Willebrand factor VIII, cytokeratin 14, 18 and 19, and α-smooth muscle actin. All cells test negative for mycoplasma, bacteria, yeast, and fungi. HIV-1, hepatitis B and hepatitis C are not detected for all donors and/or cell lots.
